GFAP and experimental autoimmune encephalomyelitis: We have demonstrated that a single intraperitoneal injection of E5415A can evoke (1) severe clinical exacerbation and produce lesions resembling NMO, including extensive loss of astrocytic markers such as AQP4, EAAT2, and glial fibrillary acidic protein (GFAP), as well as (2) perivascular deposition of IgG and C5b-C9 in the spinal cord, brainstem, and optic chiasm in rats with myelin basic protein (MBP)-induced experimental autoimmune encephalomyelitis (EAE) in which activated T cells increase the blood–brain barrier permeability [23].